Browse studies

Find your next paid study

1 recruiting study matching your filters

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlim…

Breast CancerMetastatic Breast CancerBreast Neoplasm+2 more

BriaCell Therapeutics CorporationNCT06072612